Max Christoph Liebau

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7417643/max-christoph-liebau-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91 2,005 25 43 g-index

107 2,523 5.2 4.36 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
91	Autosomal Recessive Polycystic Kidney Disease 2022 , 1-16		
90	Primary URECs: a source to better understand the pathology of renal tubular epithelia in pediatric hereditary cystic kidney diseases <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 122	4.2	O
89	Studientagung der Gesellschaft fil Piliatrische NephrologiellGrundlage innovativer Forschung. <i>Der Nephrologe</i> , 2022 , 17, 175-183	0.1	
88	A defect in molybdenum cofactor binding causes an attenuated form of sulfite oxidase deficiency. Journal of Inherited Metabolic Disease, 2021,	5.4	2
87	Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD. <i>Scientific Reports</i> , 2021 , 11, 21677	4.9	3
86	mTOR-Activating Mutations in Are Causative for Kidney Tubulopathy and Cardiomyopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2885-2899	12.7	3
85	Is There a Functional Role of Mitochondrial Dysfunction in the Pathogenesis of ARPKD?. <i>Frontiers in Medicine</i> , 2021 , 8, 739534	4.9	
84	Arterial Hypertension in a 10-Year-Old Girl. American Journal of Kidney Diseases, 2021, 77, A11-A13	7.4	
83	Autosomal Recessive Polycystic Kidney Diseases 2021 , 1-16		
82	Molecular causes of congenital anomalies of the kidney and urinary tract (CAKUT). <i>Molecular and Cellular Pediatrics</i> , 2021 , 8, 2	3.3	5
81	Targeted deletion of Ruvbl1 results in severe defects of epidermal development and perinatal mortality. <i>Molecular and Cellular Pediatrics</i> , 2021 , 8, 1	3.3	
80	Autosomal-dominante polyzystische NierenerkrankungManagement im Kindes- und Jugendalter. <i>Kinder- Und Jugendmedizin</i> , 2021 , 21, 36-42	0	
79	Early clinical management of autosomal recessive polycystic kidney disease. <i>Pediatric Nephrology</i> , 2021 , 36, 3561-3570	3.2	4
78	Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. <i>Kidney International</i> , 2021 , 100, 650-659	9.9	9
77	Translational research approaches to study pediatric polycystic kidney disease. <i>Molecular and Cellular Pediatrics</i> , 2021 , 8, 20	3.3	O
76	The carboxy-terminus of the human ARPKD protein fibrocystin can control STAT3 signalling by regulating SRC-activation. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 14633-14638	5.6	3
75	A molecular mechanism explaining albuminuria in kidney disease. <i>Nature Metabolism</i> , 2020 , 2, 461-474	14.6	35

(2019-2020)

74	Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial. <i>Scientific Reports</i> , 2020 , 10, 4294	4.9	1
73	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alports syndrome. <i>Kidney International</i> , 2020 , 97, 1275-1286	9.9	40
72	Maintenance Peritoneal Dialysis in Children With Autosomal Recessive Polycystic Kidney Disease: A Comparative Cohort Study of the International Pediatric Peritoneal Dialysis Network Registry. American Journal of Kidney Diseases, 2020, 75, 460-464	7.4	6
71	STAT signaling in polycystic kidney disease. <i>Cellular Signalling</i> , 2020 , 72, 109639	4.9	7
70	Altered molecular signatures during kidney development after intrauterine growth restriction of different origins. <i>Journal of Molecular Medicine</i> , 2020 , 98, 395-407	5.5	9
69	Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD). <i>Scientific Reports</i> , 2020 , 10, 16025	4.9	8
68	Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD). <i>Frontiers in Pediatrics</i> , 2020 , 8, 591379	3.4	1
67	Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
66	Toxigenic Corynebacterium diphtheriae-Associated Genital Ulceration. <i>Emerging Infectious Diseases</i> , 2020 , 26, 2180-2181	10.2	O
65	Systematic review on outcomes used in clinical research on autosomal recessive polycystic kidney disease-are patient-centered outcomes our blind spot?. <i>Pediatric Nephrology</i> , 2020 , 36, 3841-3851	3.2	O
64	ADPedKD: A Global Online Platform on the Management of Children With ADPKD. <i>Kidney International Reports</i> , 2019 , 4, 1271-1284	4.1	12
63	IL-6/Smad2 signaling mediates acute kidney injury and regeneration in a murine model of neonatal hyperoxia. <i>FASEB Journal</i> , 2019 , 33, 5887-5902	0.9	7
62	International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. <i>Nature Reviews Nephrology</i> , 2019 , 15, 713-726	14.9	37
61	Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). <i>Scientific Reports</i> , 2019 , 9, 7919	4.9	34
60	ATRT-07. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, ii64-ii64	1	78
59	Low levels of urinary epidermal growth factor predict chronic kidney disease progression no children. <i>Kidney International</i> , 2019 , 96, 214-221	9.9	23
58	Management von Ziliopathien im Kindes- und Jugendalter. <i>Der Nephrologe</i> , 2019 , 14, 192-198	0.1	1
57	Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. <i>Cellular Physiology and Biochemistry</i> , 2019 , 52, 1139-1150	3.9	12

56	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. <i>Radiology</i> , 2019 , 290, 769-782	20.5	45
55	Single-nephron proteomes connect morphology and function in proteinuric kidney disease. <i>Kidney International</i> , 2018 , 93, 1308-1319	9.9	32
54	Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?. <i>Pediatric Nephrology</i> , 2018 , 33, 395-408	3.2	10
53	Targeted deletion of the AAA-ATPase Ruvbl1 in mice disrupts ciliary integrity and causes renal disease and hydrocephalus. <i>Experimental and Molecular Medicine</i> , 2018 , 50, 1-17	12.8	13
52	Network for Early Onset Cystic Kidney Diseases-A Comprehensive Multidisciplinary Approach to Hereditary Cystic Kidney Diseases in Childhood. <i>Frontiers in Pediatrics</i> , 2018 , 6, 24	3.4	14
51	Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice. <i>Frontiers in Pediatrics</i> , 2018 , 6, 164	3.4	14
50	Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease. Journal of Pediatrics, 2018 , 199, 22-28.e6	3.6	28
49	Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schilein purpura nephritis: the role of early initiation and therapeutic drug monitoring. <i>Pediatric Nephrology</i> , 2018 , 33, 619-629	3.2	17
48	Perinatal Diagnosis, Management, and Follow-up of Cystic Renal Diseases: A Clinical Practice Recommendation With Systematic Literature Reviews. <i>JAMA Pediatrics</i> , 2018 , 172, 74-86	8.3	40
47	Erbliche Zystennierenerkrankungen: Autosomal-dominante und autosomal-rezessive polyzystische Nierenerkrankung (ADPKD und ARPKD). <i>Medizinische Genetik</i> , 2018 , 30, 422-428	0.5	
46	Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, i14-i26	4.5	10
45	Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech Development. <i>Neuropediatrics</i> , 2018 , 49, 379-384	1.6	9
44	FP775CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH) ON LIPOPROTEIN APHERESIS [A FOUR YEAR FOLLOW] P. Nephrology Dialysis Transplantation, 2018 , 33, i306-i307	4.3	
43	Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities. <i>Pediatric Nephrology</i> , 2017 , 32, 791-800	3.2	16
42	Challenges in establishing genotype-phenotype correlations in ARPKD: case report on a toddler with two severe PKHD1 mutations. <i>Pediatric Nephrology</i> , 2017 , 32, 1269-1273	3.2	14
41	Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1637-1643	11.6	29
40	Proteinurie im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2017 , 165, 727-736	0.2	1
39	Kidney Week 2016. <i>Der Nephrologe</i> , 2017 , 12, 45-48	0.1	

38	Nephrologische Labordiagnostik. Monatsschrift Fur Kinderheilkunde, 2017 , 165, 581-587	0.2	
37	Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease. <i>Frontiers in Pediatrics</i> , 2017 , 5, 18	3.4	11
36	CliniciansSattitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , 2017 , 12, e0185779	3.7	19
35	Bicarbonate buffered peritoneal dialysis fluid upregulates angiopoietin-1 and promotes vessel maturation. <i>PLoS ONE</i> , 2017 , 12, e0189903	3.7	5
34	A case report on the exceptional coincidence of two inherited renal disorders: ADPKD and Alport syndrome?. <i>Clinical Nephrology</i> , 2017 , 88, 45-51	2.1	3
33	Syndromale und ziliEe Erkrankungen1 2017 , 151-167		
32	Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing. <i>Pediatric Nephrology</i> , 2016 , 31, 73-81	3.2	19
31	Quiz Page December 2016: Anuria on the Second Day Following Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2016 , 68, A18-A21	7.4	1
30	Nieren aus der Petrischale. <i>Der Nephrologe</i> , 2016 , 11, 66-67	0.1	
29	Polycystic Kidney Disease: ADPKD and ARPKD 2016 , 333-367		1
29	Polycystic Kidney Disease: ADPKD and ARPKD 2016 , 333-367 Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9	3.2	30
	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic	3.2	
28	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9		
28	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9 Zystennieren im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2015 , 163, 343-351 Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> ,	0.2	30
28 27 26	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9 Zystennieren im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2015 , 163, 343-351 Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015 , 16, 22 Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function. <i>Molecular and</i>	0.2	30
28 27 26 25	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9 Zystennieren im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2015 , 163, 343-351 Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015 , 16, 22 Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function. <i>Molecular and Cellular Pediatrics</i> , 2015 , 2, 8	o.2 2.7 3.3	30 33 30
28 27 26 25 24	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 274-9 Zystennieren im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2015 , 163, 343-351 Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015 , 16, 22 Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function. <i>Molecular and Cellular Pediatrics</i> , 2015 , 2, 8 Autosomal-rezessive polyzystische Nierenerkrankung. <i>Der Nephrologe</i> , 2014 , 9, 312-318 Consensus expert recommendations for the diagnosis and management of autosomal recessive	0.2 2.7 3.3	30 33 30 5

20	Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT). <i>Journal of Molecular Medicine</i> , 2013 , 91, 739-48	5.5	29
19	Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. <i>Pediatric Nephrology</i> , 2013 , 28, 1771-83	3.2	25
18	Dysregulated autophagy contributes to podocyte damage in Fabry's disease. <i>PLoS ONE</i> , 2013 , 8, e63506	53.7	79
17	Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. <i>Cell</i> , 2012 , 150, 533-48	56.2	266
16	AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. <i>EMBO Journal</i> , 2012 , 31, 3961-75	13	46
15	The centrosomal kinase Plk1 localizes to the transition zone of primary cilia and induces phosphorylation of nephrocystin-1. <i>PLoS ONE</i> , 2012 , 7, e38838	3.7	37
14	The ciliary protein nephrocystin-4 translocates the canonical Wnt regulator Jade-1 to the nucleus to negatively regulate Etatenin signaling. <i>Journal of Biological Chemistry</i> , 2012 , 287, 25370-80	5.4	36
13	Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2662-7	15.9	132
12	NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. <i>Journal of Cell Biology</i> , 2011 , 193, 633-42	7.3	116
11	Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of nephrocystin-1 to control targeting to monocilia. <i>Journal of Biological Chemistry</i> , 2011 , 286, 14237-45	5.4	19
10	PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. <i>Journal of Clinical Investigation</i> , 2011 , 121, 821-821	15.9	2
9	PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1812-23	15.9	168
8	Nephrotisches Syndrom. <i>Der Nephrologe</i> , 2009 , 4, 453-467	0.1	
7	Bauchschmerzen, Erbrechen und Diarrh Monatsschrift Fur Kinderheilkunde, 2009 , 157, 108-112	0.2	
6	Atypical Alport syndrome associated with a novel COL4A5 mutation. Clinical Nephrology, 2009, 71, 321-	52.1	
5	L1CAM mutation in a boy with hydrocephalus and duplex kidneys. <i>Pediatric Nephrology</i> , 2007 , 22, 1058-	631.2	7
4	Functional expression of the renin-angiotensin system in human podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, F710-9	4.3	98
3	Upregulation of Id-1 via BMP-2 receptors induces reactive oxygen species in podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, F654-62	4.3	16

2 Autosomal-rezessive polyzystische Nierenerkrankung (ARPKD). Der Nephrologe,1

0.1

Handlungsempfehlung nach der S2k-Leitlinie Nierenzysten und zystische Nierenerkrankungen bei Kindern Monatsschrift Fur Kinderheilkunde, 1

0.2